← Eichor
Condition: Blood Cancers Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Blood Cancers

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06245746A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07043894Activity Levels in Bone Marrow Transplant Patients
Phase N/A · 1 location(s) · Michael Tomasson · NCT04115241Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT00083512AnovaOS Network Powered Patient Registry
Phase N/A · 1 location(s) · Anova Enterprises, Inc · NCT05013944Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hemato
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07235501Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · University of Rochester · NCT05597345A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomi
Phase 2 · 16 location(s) · Karyopharm Therapeutics Inc · NCT04414475The MARVIN Chatbots to Provide Information for Different Health Conditions
NA · 2 location(s) · McGill University Health Centre/Research Institute of the Mc · NCT05789901A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or R
Phase 3 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT07452198Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Phase N/A · 1 location(s) · University of Missouri-Columbia · NCT02838836Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administ
Phase 1/Phase 2 · 8 location(s) · SNIPR Biome Aps. · NCT06938867The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
NA · 1 location(s) · Guangdong Provincial People's Hospital · NCT06244264AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363Chemotherapy Supported by Autologous Hematopoietic Stem Cells
NA · 1 location(s) · Chongqing University Cancer Hospital · NCT05401162Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06561854Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · 71 location(s) · Merck Sharp & Dohme LLC · NCT06395103Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese
Phase N/A · 1 location(s) · Ruijin Hospital · NCT05870969MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Collection and Distribution of Biospecimens for Novel Research Uses
Phase N/A · 2 location(s) · iSpecimen Inc · NCT03848962An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
Phase N/A · 1 location(s) · The Royal Wolverhampton Hospitals NHS Trust · NCT04234022Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Phase 2 · 1 location(s) · Stanford University · NCT06461988Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05776979Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Phase 2 · 29 location(s) · European Myeloma Network B.V. · NCT07107529All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06158412Discontinuation Study
NA · 1 location(s) · University College Cork · NCT05866757
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.